Sava Company Overview, Contact Details & Competitors

Q: What is Sava's official website and social media links?

Sava's official website is sava.health. Sava has social profiles on LinkedIn.

Q: How many employees does Sava have currently?

Sava has approximately 118 employees.

Q: What technology does Sava use?

Sava's tech stack includes React, Webpack, SOLIDWORKS PDM, MATLAB, reCAPTCHA.

Insights

Gathering insights about Sava…

Similar companies to Sava

Philips
$10B

Sava Tech Stack

Sava uses 8 technology products and services including JSON-LD, Lodash, Android SDK, and more. Explore Sava's tech stack below.

JSON-LD
Javascript Frameworks
Lodash
Javascript Libraries
Android SDK
Mobile Application Development Platforms
WordPress.com
Platform As A Service
Microsoft Azure
Platform As A Service
Android
Programming Languages
Python
Programming Languages
Google
Search Engines

Media & News

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders.
Dec 24, 2025 | www.prnewswire.com
Cassava Announces Agreement to Settle Securities Class Action Litigation
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it has reached a definitive agreement to resolve the previously disclosed consolidated securities class action litigation pending in the United States District Court for the Western District of Texas Austin Division (In re Cassava Sciences, Inc. Securities Litigation, No. 1:21-cv-00751-DAE) (the “Consolidated Securities Action”). This lawsuit was originally filed in 2021.
Dec 23, 2025 | www.globenewswire.com
FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold
Cassava Sciences Inc. (NASDAQ: SAVA) received a formal letter from the U.S. Food and Drug Administration (FDA) related to the company's trial for simufilam
Dec 19, 2025 | www.benzinga.com
Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)
Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Cassava Sciences (NASDAQ: SAVA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Institutional and Insider Ownership 44.3% of Carisma
Nov 05, 2025 | www.defenseworld.net
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders. If you currently own Cassava stock and acquired shares on or before September 14, 2020, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to l.
Oct 22, 2025 | www.businesswire.com
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board).
Oct 22, 2025 | www.globenewswire.com
Cassava Reports Q2 2025 Financials Results and Provides Business Update
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2025 and provided a business update.
Aug 14, 2025 | www.globenewswire.com

Sava's Email Address Formats

Sava uses at least 2 format(s):

Sava Email Formats	Example	Percentage
First@caura.me	John@caura.me	94%
First.L@caura.me	John.D@caura.me	6%
First@sava.health	John@sava.health	100%

Frequently Asked Questions

Where is Sava's headquarters located?

Sava's main headquarters is located at 117 Charterhouse Street London, England ec1m 6aa United Kingdom. The company has employees across 5 continents, including EuropeAsiaNorth America.

What is Sava's stock symbol?

Sava is a publicly traded company; the company's stock symbol is SAVA.

What is Sava's official website and social media links?

Sava's official website is sava.health and has social profiles on LinkedIn Crunchbase.

What is Sava's SIC code NAICS code?

Sava's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Sava have currently?

As of February 2026, Sava has approximately 118 employees across 5 continents, including EuropeAsiaNorth America. Key team members include Vice President Of Manufacturing: C. D.Head Of Operations: O. S.Head Of Systems & Software: J. P. M. A.. Explore Sava's employee directory with LeadIQ.

What industry does Sava belong to?

Sava operates in the Biotechnology Research industry.

What technology does Sava use?

Sava's tech stack includes JSON-LDLodashAndroid SDKWordPress.comMicrosoft AzureAndroidPythonGoogle.

What is Sava's email format?

Sava's email format typically follows the pattern of First@caura.me. Find more Sava email formats with LeadIQ.

How much funding has Sava raised to date?

As of February 2026, Sava has raised $19M in funding. The last funding round occurred on Jul 30, 2025 for $19M.

When was Sava founded?

Sava was founded in 2016.

Insights

Similar companies to Sava

Philips

Sava Tech Stack

Media & News

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Cassava Announces Agreement to Settle Securities Class Action Litigation

FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Sava's Email Address Formats

Frequently Asked Questions

Where is Sava's headquarters located?

What is Sava's stock symbol?

What is Sava's official website and social media links?

What is Sava's SIC code NAICS code?

How many employees does Sava have currently?

What industry does Sava belong to?

What technology does Sava use?

What is Sava's email format?

How much funding has Sava raised to date?

When was Sava founded?

Sava

Company Overview

Media & News

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Cassava Announces Agreement to Settle Securities Class Action Litigation

FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?